Elias Rawad, Morales Joshua, Presley Carolyn
Section of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Section of Geriatrics, Boston University School of Medicine, Boston, MA, USA.
Curr Oncol Rep. 2017 Sep;19(9):62. doi: 10.1007/s11912-017-0619-0.
Non-small cell lung cancer (NSCLC) is mostly a disease of older adults, with its incidence and mortality rates increasing exponentially after the age of 65 years. Immune checkpoint inhibitors (ICIs) have changed the scene of NSCLC treatment after a long and relatively stagnant period of standard treatment regimens. However, little is known about the specific impact of these agents in older adults for whom care is often complicated by a variety of syndromes. This underlines the importance of understanding the dynamics of new cancer treatments in an older patient population. In this paper, we will review ICIs' mechanism of action and data from published clinical trials relevant to older adults. In addition, we will discuss immune aging and treatment-related toxicity as potential challenges facing the use of checkpoint inhibitors in older adults with NSCLC.
非小细胞肺癌（NSCLC）主要是一种老年疾病，其发病率和死亡率在65岁之后呈指数级增长。在经过漫长且相对停滞的标准治疗方案阶段后，免疫检查点抑制剂（ICIs）改变了NSCLC的治疗局面。然而，对于这些药物在老年患者中的具体影响知之甚少，因为老年患者的护理常常因各种综合征而变得复杂。这凸显了了解老年患者群体中新癌症治疗动态的重要性。在本文中，我们将回顾ICIs的作用机制以及来自已发表的与老年患者相关的临床试验数据。此外，我们还将讨论免疫衰老和治疗相关毒性，这些是老年NSCLC患者使用检查点抑制剂时面临的潜在挑战。
